Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892833) titled 'Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Bengbu Medical University
Condition:
ESCC
Intervention:
Drug: Becotatug vedotin (MRG003)
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: May 1, 2026
Target Sample Size: 38
Countries of Recruitment:
China
T...